汉森制药
(002412)
| 流通市值：25.74亿 | | | 总市值：26.32亿 |
| 流通股本：4.92亿 | | | 总股本：5.03亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 65,600,648.7 | 109,095,075.24 | 143,953,813.25 | 145,405,613.92 |
| 应收票据及应收账款 | 281,247,117.68 | 287,200,143.64 | 281,261,608.11 | 276,273,295.8 |
| 其中：应收票据 | 45,717,236.67 | 41,851,244.32 | 42,551,815.92 | 44,094,392.55 |
| 应收账款 | 235,529,881.01 | 245,348,899.32 | 238,709,792.19 | 232,178,903.25 |
| 应收款项融资 | 44,021,602.22 | 44,912,228.86 | 46,082,395.57 | 44,299,344.54 |
| 预付款项 | 4,699,495.1 | 2,583,080.9 | 3,904,640.66 | 4,215,857.83 |
| 其他应收款合计 | 12,945,537.54 | 16,316,446.36 | 16,822,602.22 | 11,957,433.09 |
| 存货 | 241,209,397.82 | 237,447,264.62 | 240,313,858.24 | 246,617,154.53 |
| 其他流动资产 | 20,460,021.54 | 19,387,320.19 | 285,255.83 | 811,719.93 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 830,305,842.99 | 816,525,600.44 | 933,341,824.23 | 865,402,215.15 |
| 非流动资产: | | | | |
| 长期股权投资 | 817,978,477.94 | 831,263,844.38 | 799,235,017.58 | 781,349,567.83 |
| 投资性房地产 | 3,681,900.07 | 3,746,072.89 | 3,810,245.71 | 3,874,418.53 |
| 固定资产 | 400,948,486.12 | 407,662,640.12 | 417,227,419.67 | 425,652,140.6 |
| 在建工程 | 7,517,229.49 | 6,518,080.48 | 6,209,078.23 | 6,091,302.08 |
| 生产性生物资产 | 8,533,754.24 | 8,279,858.1 | 7,686,026.86 | 7,709,780.54 |
| 无形资产 | 30,666,932.5 | 31,717,968.97 | 32,226,427.59 | 33,720,809.45 |
| 商誉 | 14,789,430.33 | 14,789,430.33 | 14,789,430.33 | 14,789,430.33 |
| 长期待摊费用 | 15,306,574.61 | 15,486,245.63 | 15,609,687.77 | 15,712,291.59 |
| 递延所得税资产 | 1,862,904.67 | 1,917,245.9 | 1,976,356.31 | 2,044,428.26 |
| 其他非流动资产 | 138,148,158.94 | 140,771,265.17 | 136,511,751.97 | 134,597,665.69 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,439,433,848.91 | 1,462,152,651.97 | 1,435,281,442.02 | 1,425,541,834.9 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,269,739,691.9 | 2,278,678,252.41 | 2,368,623,266.25 | 2,290,944,050.05 |
| 流动负债: | | | | |
| 短期借款 | 90,105,891.98 | 130,131,280.94 | 120,150,197.61 | 120,150,197.65 |
| 应付票据及应付账款 | 29,102,821.8 | 29,889,809.83 | 34,252,555.86 | 43,630,773.33 |
| 应付账款 | 29,102,821.8 | 29,889,809.83 | 34,252,555.86 | 43,630,773.33 |
| 合同负债 | 1,047,109.15 | 1,406,758.44 | 1,750,005.5 | 7,019,852 |
| 应付职工薪酬 | 23,954,361.36 | 23,768,601.23 | 23,328,645.44 | 41,139,659.06 |
| 应交税费 | 3,517,858.91 | 4,892,703.3 | 18,556,261.81 | 15,970,808.27 |
| 其他应付款合计 | 226,350,942.95 | 203,271,285.88 | 173,388,152.64 | 132,603,923.44 |
| 其他流动负债 | 13,906,219.84 | 21,830,886.01 | 23,559,297.8 | 19,721,941.94 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 387,985,205.99 | 415,191,325.63 | 394,985,116.66 | 380,237,155.69 |
| 非流动负债: | | | | |
| 递延收益 | 16,410,019.37 | 16,950,683.33 | 17,491,347.29 | 15,032,011.25 |
| 递延所得税负债 | 1,153,541.27 | 1,229,113.05 | 1,356,199.13 | 1,543,180.19 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 17,563,560.64 | 18,179,796.38 | 18,847,546.42 | 16,575,191.44 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 405,548,766.63 | 433,371,122.01 | 413,832,663.08 | 396,812,347.13 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 503,200,000 | 503,200,000 | 503,200,000 | 503,200,000 |
| 资本公积 | 234,116,276.27 | 234,116,276.27 | 234,116,276.27 | 234,116,276.27 |
| 其他综合收益 | 6,777,288.75 | 6,968,635.59 | 1,091,801.92 | -4,499,616.15 |
| 盈余公积 | 157,692,390.54 | 157,692,390.54 | 157,692,390.54 | 157,692,390.54 |
| 未分配利润 | 962,404,969.71 | 943,329,828 | 1,058,690,134.44 | 1,003,622,652.26 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,864,190,925.27 | 1,845,307,130.4 | 1,954,790,603.17 | 1,894,131,702.92 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,864,190,925.27 | 1,845,307,130.4 | 1,954,790,603.17 | 1,894,131,702.92 |
| 负债和股东权益合计 | 2,269,739,691.9 | 2,278,678,252.41 | 2,368,623,266.25 | 2,290,944,050.05 |
| 公告日期 | 2023-10-28 | 2023-08-29 | 2023-04-29 | 2023-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |